One plausible explanation for acquisition of drug resistance, relapse, and metastasis in luminal tumors is the presence of drug extruding, tumor-initiating cells (TICs). The phenotype of TICs is defined as being relative quiescent, compared to the majority of tumor cells, with heightened expression of multi-drug resistant pumps, such as members of the ABC transport family [5] , and lower levels of reactive oxygen species [6] . These properties would confer a selective advantage in avoiding therapeutic drugs. TICs in primary human breast cancers are described as Lin -CD44 ? CD24 -/low , epithelial specific antigen (ESA)
? [7] . CD44 ? CD24 -/low cells are relatively resistant to standard chemotherapies [8, 9] and radiation therapy [6, 10] compared to non CD44
? CD24 -/low tumor cells. CD44
? CD24 -/low cells also contain a stem-like and invasive gene signature which is itself a predictor of metastasis free survival [11, 12] . However, other studies have found no association between the actual prevalence of these cells in human breast tumors and overall survival [13, 14] . Thus, there remains a need for more specific markers to define the drug resistant cells within the CD44
? CD24 -/low fraction. One such marker, aldehyde dehydrogenase 1 (ALDH1) additionally specifies TICs within the CD44
? CD24
-/low fraction of TNP breast tumors, but appears to be absent in luminal ER ? breast cancer cell lines and tumors [15, 16] . This underscores the need to better define TICs in common luminal ER
? breast cancers, and their role in drug resistance and recurrence in luminal disease. It has been postulated that ER -subpopulations within ER ? luminal breast cancers harbor such TICs [17] .
We previously identified a subpopulation of cells that exist within the CD44
? CD24 -/low TIC fraction of luminal ER ? PR ? tumor xenografts that are positive for CK5 [18] . The latter is a signature marker of poor prognostic ER -basal breast tumors [2] . In fact, the CK5
? cells in luminal tumors lack ER and PR as well. CK5 has been implicated as a marker of both stem cells and bi-potent progenitor cells in the normal breast [19] [20] [21] 
Materials and methods

Reagents
The human breast cancer cell lines T47D and MCF7 were originally obtained from Iafa Keydar [22] , and Sam Brooks, the Michigan Cancer Foundation, respectively. They were maintained in MEM supplemented with 0.2 units/ml insulin and 5% fetal bovine serum (FBS). Both cell lines are ductal carcinomas isolated from pleural effusions of breast cancer patients. Cell line authenticity was confirmed by short tandem repeat analyses in the University of Colorado DNA Sequencing Core Laboratory. Antibodies were mouse mAb to CK5 (XM26, Novacastra, UK); rabbit mAb to ER (SP1, Lab Vision, Fremont, CA); mouse mAb to PR (1294, DAKO, Carpinteria, CA), rabbit pAb to cleaved caspase 3 (Promega); rabbit pAb to cleaved poly (ADP-ribose) polymerase (PARP, Danvers, MA), and mouse mAb to b-actin (A5316, Sigma-Aldrich, St. Louis, MO). 17b-estradiol (E), 6a-Methyl-17a-hydroxyprogesterone acetate (MPA), 5-Fluorouracil, 4-hydroxytamoxifen, 5-bromo-2-deoxyuridine (BrdU), and 4 0 , and 6-diamidino-2-phenylindole (DAPI) were purchased from Sigma (St. Louis, MO). Docetaxel was purchased from LC Labs (Woburn, MA), and ICI-182780 from Tocris Bioscience (Ellisville, MO). Reduced growth factor Matrigel was from BD Biosciences (Franklin Lakes, NJ).
Cell culture and drug treatments T47D cells were isolated from xenograft tumors as previously described [18] and are termed T47D T cells. For twodimensional (2D) culture, T47D T and MCF7 cells were seeded in 60-mm dishes onto glass coverslips at 10 5 cells/ well in phenol red-free 5% dextran-coated, charcoal-stripped media. Dose-response curves were performed for 5-FU and Dx in T47D and MCF7 cells using MTT assays and concentrations chosen that elicited a 80-90% cytoreduction after 3 days. For chemotherapy experiments, cells were either treated with vehicle (ethanol), 150 lM 5-fluorouracil (5-FU) or 10 nM docetaxel (Dx) for 3 days. For hormone therapy, cultures were either unsupplemented (estrogen withdrawal, EWD), or supplemented with 10 nM E alone, E ? 100 nM 4-hydroxytamoxifen (Tam), or E ? 100 nM ICI-182780 (fulvestrant). Cultures were incubated for 3 weeks under each of these conditions, replenishing media and hormones every other day. Three-dimensional (3D) culture of cells in Matrigel was previously described [18] . For the current 3D experiments, 10 4 cells were seeded onto Matrigel on day 1 in MEM plus 5% dextran-coated charcoal-stripped FBS. Cells were treated with vehicle, 150 lM 5-FU, or 10 nM Dx for 3 days prior to fixation and paraffin embedding. For some experiments, cells were treated 1 day prior to drug treatments with either 100 nM MPA (P, T47D) or a combination of 10 nM E plus 100 nM MPA (E ? P, MCF7), which expands the population of CK5 ? cells [18, 23] . Cultures were incubated with 0.25 mg/ml (BrdU) for 1 h prior to collection and fixation.
Immunocytochemistry and immunohistochemistry
Breast cancer tissue arrays were purchased from Biochain (Hayward, CA). These were stained by immunohistochemistry (IHC) with an EnVision TM G|2 Doublestain System (DAKO) with antibodies to ER (DAB, brown) or PR (DAB, brown), and CK5 (Alkaline phospatase (AP), fast red). For cells in 2D culture, cells were fixed onto glass coverslips in ice cold 70% acetone/30% methanol for 5 min and stained by immunocytochemistry (ICC) with antibodies to CK5/ER, CK5/PR, or CK5/BrdU. 3D cultures were formalin fixed and paraffin embedded as previously described [18] . Sections (5 lm) were dual stained using the antibody combinations CK5/BrdU, or CK5/cleaved caspase 3, or CK5/cleaved PARP where the second antibodies were rabbit mAbs. Secondary antibodies were anti-mouse and anti-rabbit Alexa Fluors 488 (green) and 555 (red)-conjugated, respectively. A Nikon E600 microscope was used for photography. Images were shot in black and white using ImagePro software (Media Cybernetics) and merged in Adobe Photoshop CS3 (Adobe).
Immunoblots
Protein extracts were prepared from T47D cells following treatments by solubilizing cells in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton, 1% sodium deoxycholate (SOC), 0.1% SDS) supplemented with protease and phosphatase inhibitors. Protein concentrations were determined by Bradford assay. Cell extracts (50 lg of total protein) were resolved on 10% SDS-PAGE gels, transferred to nitrocellulose, and probed with monoclonal antibodies to ER, CK5, or b-actin. Bands were visualized by enhanced chemiluminescence. Bands were quantified by gel scanning and densitometry with an Alpha Imager 2200 (Alpha Innotech, San Leandro, CA).
Clinical array data
Details of an ongoing randomized phase II clinical trial investigating neoadjuvant treatment with exemestane alone, or exemestane plus tamoxifen have been described [24] . Briefly, women with locally advanced ER ? breast cancers underwent treatments for 4 months. Tumor samples were obtained pre-treatment via core needle biopsies, and posttreatment at the final excision surgery. For this study, paraffin sections of tumors pre-and post-treatment (6 pairs) were immunostained with an mAb to CK5 (EnVision TM , DAKO, permanent red). Labeled cRNA was prepared from tumor pieces, hybridized to HGU133 Plus 2.0 Affymetrix oligonucleotide microarray chips, and analyzed as described [24] . Normalized expression levels (Genespring 7.3, Agilent Technologies) for the ER (ESR1) and CK5 (KRT5) probesets were determined pre-and post-therapy (n = 6 pairs). The protocol was approved by the Colorado Multiple Institutional Review Board. Informed consent was obtained from all patients prior to participation.
Biostatistics
Graphpad Prism software (version 4.0) was used to analyze and graph all data. For 2D culture, multiple fields (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were counted and statistical significance was determined by Student's t test (two groups), or one-way ANOVA/ Dunnett's post test (three groups). For 3D culture, individual colonies (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were counted and statistical significance determined by one-way ANOVA/Tukey (three groups) or Student's t test (two groups). For tumor sections (primary, T47D, MCF7), CK5
? cells were scored for ER and PR staining, plotted as the average percent positive and negative for each, and analyzed by Student's t test. Primary tumors pre-and post-neoadjuvant endocrine therapy were scored for the number of CK5
? cells across multiple fields, plotted, and analyzed by paired t test. Paired t tests were also used to analyze normalized gene expression of specific probesets from previously described microarray data [24] . ? cells on both 2D plastic and in 3D Matrigel culture, at similar levels to the tumors from which they were derived [18] . For the majority of experiments described here, we use the T47D T cells as a model to study the relative resistance of CK5 ? cells to therapies compared to the majority CK5 -cells. We have also previously demonstrated that treatment with a combination of estrogen-plus progestin (E ? P), but not estrogen alone (E), increases the number of CK5
Results
A subpopulation of cells of with an ER
? cells from 0-2 to 10-20% in breast cancer cell lines and xenograft tumors derived from these cell lines [23, 25] ? cells for this analysis [23] . BrdU (0.25 mg/ml) was added to cultures 1 h prior to harvest. Cells in 2D were fixed and dual fluorescent ICC was performed for ER/CK5, PR/CK5, BrdU/CK5, or BrdU/PR (T47D T ). Cells in 3D were fixed in paraformaldehyde, embedded into paraffin blocks, and stained by dual IHC for BrdU/CK5. All samples were counterstained with DAPI. The CK5
? (green) cells are negative for both ER and PR ([95% ER -PR -, indicated by arrows), similar to that observed in primary and xenograft tumors (Fig. 1) ? cells in T47D T (6.5%) and MCF7 cultures (2.2%) (t test at P \ 0.01 and P \ 0.001, respectively). Dual staining for CK5/Ki67 yielded similar results (not shown). We conclude that in luminal breast cancer cell lines, the minority CK5
? population has a lower proliferative rate relative to the majority CK5 -cells.
Chemotherapy treatment enriches for CK5
? cells in T47D T cultures
We speculated that CK5
? cells would be less sensitive to chemotherapy agents that target cell division, compared to the more rapidly dividing CK5
-cells. To test this, T47D T cells were plated at 10 5 cells/60 mm well in 2D culture allowed to expand for 3 days, and then treated with vehicle, 150 lM 5-FU, or 10 nM Dx for 3 days. Cultures were fixed and stained for CK5 by ICC, and counterstained with DAPI. Figure 3a shows representative fields stained for CK5 following treatment with vehicle (control), 5-FU or Dx. Ten-12 fields per condition were scored for total cells (DAPI ? ) and CK5 ? cells. These were plotted as a percent of total cells for each treatment in Fig. 3b . The average percent of CK5
? cells/field in control cells was 22.2%; this increased to 29.9 and 41.0% CK5
? cells/field in 5-FU and Dx-treated cells, respectively. These were statistically significant (ANOVA/Dunnett's, P \ 0.05 control vs. 5-FU, P \ 0.01 control vs. Dx). Similar results were obtained for T47D cells treated with P (not shown). Longer treatment times and higher chemical doses could eradicate both populations of tumor cells. These data confirm that CK5 ? cells become enriched 1.4-2 fold in cultures treated with chemotherapy agents that target DNA replication. figure  online) were scored for each treatment group, and data were graphed as the total number of CK5
-and CK5 ? cells that were also cl. caspase 3 ? (Fig. 4b) . There was no statistical difference in cl. caspase 3 staining between CK5
-and CK5
? cells in control T47D T colonies (2.0 and 0.0%, respectively). In 5-FU-treated T47D T -cells, potentially due to their slower proliferation rate and/or less uptake of the drugs. Furthermore, the population of CK5
? cells (i) in cultures isolated from tumors, and (ii) induced by P treatment are equally resistant to these drugs, suggesting the two populations are likely the same.
A parallel decrease in ER and increase in CK5 protein levels in T47D T cells treated with endocrine therapy agents
We postulated that the ER -PR -status of CK5 ? cells would also make them less sensitive to endocrine therapy drugs targeting the estrogen/ER-dependent growth of tumor cells. To test this, T47D T cells were plated into phenol red-free, charcoal-stripped media containing vehicle (estrogen withdrawal (EWD)), 10 nM E, E ? 100 nM Tam, or E ? 100 nM ICI-182780. After 3 weeks of treatment, whole cell extracts were prepared from cells and separated by SDS-PAGE. Immunoblots were probed with antibodies to ER, CK5, and b-actin (Fig. 5a) . In E-treated cultures, ER was clearly present while CK5 expression was extremely low. Under EWD conditions (to mimic aromatase inhibitor (AI) therapy), ER protein levels decreased 2.7-fold, and CK5 protein levels increased 3.2-fold. Addition of Tam or ICI-82780 to E abrogated the effect of the estrogen. In these samples, ER protein levels decreased 2.3-and 3.4-fold, while CK5 protein levels increased 2.4-and 3.4-fold. PR protein levels were also decreased (not shown). These data suggest that endocrine therapy of luminal breast cancer cells increases a ER -PR -CK5 ? subpopulation while decreasing the ER ? PR ? CK5 -population. To assess ER levels in chemotherapy-treated cells, T47D T cells in 2D culture were treated with 5-FU as described, and whole cell extracts were prepared. Immunoblots were performed on extracts from control and 5-FU-treated cells, and probed with antibodies to ER or b-actin (Fig. 5b) . ER protein is present in control cells, but is reduced *threefold in 5-FU-treated cultures.
Loss of ER and gain of CK5 expression in ER
? tumors from patients treated with neoadjuvant endocrine therapy To determine if the observed decrease in ER and increase in CK5 expression occurs in clinical samples, we performed analysis on a small set of tumor samples obtained from a phase II study of neoadjuvant exemestane (AI) with or without tamoxifen (described in [24] this trial. Microarray expression analyses on six pairs of samples pre-and post-treatment were previously reported [24] . We extracted normalized expression data for specific probe sets of interest (CK5, ER) from the microarray database and graphed these as mean expression levels preand post-treatment (six samples each) (Fig. 6c ). These were not clustered into treatment type (AI, or AI ? Tam) or responders/non-responders for this study, because of the small sample size. The gene probes for ER (ESR1) decreased significantly from normalized levels of 56.7 ± 17.2 in pre-treatment tumors to 18.3 ± 5.3 in posttreatment tumors (paired t test, P \ 0.05). The gene probes for CK5 (KRT5) increased significantly from 8.9 ± 3.8 in pre-treatment tumors, to 20.8 ± 5.2 in post-treatment tumors (paired t test, P \ 0.05). Primary pre-treatment ER ? tumors varied in PR status. Collectively, expression of the gene for PR tended towards a decrease between preand post-treatment samples, but was not significant (not shown). Paraffin sections from the six sets of tumors (preand post-treatment) were stained by IHC for CK5 (Fig. 6a , two pairs shown). Pre-treatment tumors contained rare single CK5
? cells, while post-treatment tumors had patches of CK5
? cells. Sections were scored for the average number of CK5
? cells/field across each biopsy and are plotted in Fig. 6b . The average number of CK5 ? cells/field increased in post-treatment samples (30.4 ± 11.3) compared to pre-treatment (2.6 ± 2.0) samples (paired t test, P \ 0.05). These data corroborate the in vitro cell line data, demonstrating that a simultaneous decrease in ER and increase in CK5 expression occurs in ER ? tumors undergoing neoadjuvant endocrine therapy. We conclude that while ER
? cells are reduced in number by endocrine therapy, the ER -CK5 ? cells are immune to ER targeted therapies, and would survive to repopulate the tumor.
Discussion
Resistance to hormonal and conventional therapies remains a critical problem for patients with ER ? breast cancers. Most studies have focused on de novo or acquired resistance of the majority ER ? cells in these tumors. In this study, we demonstrate that a population of cells within luminal ER
? breast cancers that lack ER and PR, and express CK5 resists treatment with endocrine and chemotherapies. These ER -PR -CK5 ? cells are a subpopulation of the CD44
? CD24 -/low TIC fraction and may represent a more specific marker of drug resistant cells in luminal disease. At first glance these cells appear phenotypically similar to those found in aggressive basal breast tumors, which are also steroid receptor negative, CK5
? , and are enriched in CD44
? CD24 -/low cells [14, 25] . These basal tumors have a higher pathologic grade and proliferative index, and their initial response to chemotherapy is actually more robust than the response of luminal, ER ? tumors [26] . [27] [28] [29] . Interestingly, Abd El-Rehim et al. [27] described a set of tumors with combined luminal and basal CK markers that had worse prognosis than tumors expressing pure luminal CKs. CK5/6 alone was shown to be an independent indicator of relapse-free survival [27] . Furthermore, CK5 expression can divide TNP tumors into those with more (CK5 -) or less favorable (CK5 ? ''basal'') prognoses [25] . Our data support the hypothesis that many ER ? tumors ([50%) have a mixed luminal and basal CK profile. This phenotype translates to many commonly studied ER ? PR ? breast cancer cell lines (T47D, MCF7, ZR75-1, BT474), especially when they are grown as solid tumor xenografts in vivo. We have also demonstrated that hormonal signals, specifically progestin treatment, increases the number of CK5
? cells both in vitro and in xenograft tumors [18, 23] . Here, we use cells directly isolated from tumors that harbor a constitutive CK5
? population, and demonstrate that the CK5
? cells preferentially survive endocrine and chemotherapies. Microarray expression analyses and IHC confirm that the luminal located CK5
? cells co-express other basal CKs such as 6 and 17 [18] . These data provide a plausible ? tumors from a phase II clinical trial were treated with neoadjuvant tamoxifen plus/ minus exemestane for 4 months. Tumor samples were collected preand post-treatment. a mRNA levels for the genes encoding ER (ESR1) and CK5 (KRT5) were compared from published microarray data sets from these tumors (n = 6 pairs) [24] . Normalized expression levels plus/minus SEM are depicted. * P \ 0.05, paired t test. b Sections from pre-and post-treatment tumors were immunostained for CK5 (n = 6 pairs). Two representative sections each of pre-and post-treatment tumors are shown. c Sections were scored for CK5 staining and plotted as number of cells per field plus/minus SEM (n = 6 pairs). * P \ 0.05, paired t test explanation as to why luminal tumors with a mixed luminal/basal CK phenotype have poorer outcome.
Biological explanations for endocrine resistance in up to one-third of ER ? breast tumors continue to be sought [4] . ER ? cells can bypass dependency on ER signaling, and use alternate growth factor signaling pathways for survival [4] . A fraction of ER ? tumors (20-30%) will progressively lose expression of ER and assume a more untreatable de-differentiated phenotype [30, 31] . Of note is the fact that luminal ER ? tumors acquire the CD44 ? CD24 -/low phenotype following letrozole or docetaxel treatment [32] . EGFR and HER2 expression are also upregulated following endocrine therapies, with down regulation of ER and estrogen-responsive genes [33, 34] . This is consistent with our data, where CK5
? cells, which co-express EGFR ? and CD44
? , are enriched following endocrine treatments. We put forward that in ER ? luminal tumors, the ER -PR -CK5
? subpopulation expands during treatment as a means of survival. In the normal breast, ER -cells are stimulated to divide via a paracrine mechanism from surrounding quiescent ER ? cells [35] . In breast tumors, the transformed ER 
